In a nutshell This study evaluated the effectiveness and safety of olaparib (Lynparza) with or without cediranib (Recentin) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that cediranib combined with olaparib significantly improved survival without cancer worsening compared with olaparib alone in these patients....
Read MoreType of prostate cancer-Adenocarcinoma Posts on Medivizor
Evaluating the effectiveness of degarelix with or without apalutamide before prostate surgery in patients with high-risk prostate cancer.
In a nutshell This study evaluated the effectiveness of degarelix (Firmagon) with or without apalutamide (Erleada) before radical prostatectomy (RP; prostate surgery) in patients with high-risk prostate cancer (PC). The data showed that degarelix plus apalutamide significantly improved the pathological response in these patients. Some background...
Read MoreEvaluating the long-term outcomes of radiotherapy added to standard therapy for men with metastatic prostate cancer.
In a nutshell The study investigated whether radiotherapy (RT) addedd to standard of care (SOC) treatment would be beneficial for men with metastatic (spread) prostate cancer (mPC). The study showed that adding RT to SOC improved the survival of men with low burden (defined as fewer than 10 lesions, no greater than 3cm in diameter) mPC. Some...
Read MoreEvaluating the effects of olaparib on pain and the health-related quality of life in patients with metastatic castration-resistant prostate cancer.
In a nutshell This study evaluated the effects of olaparib (Lynparza) on pain and the health-related quality of life (HR-QoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations (genetic abnormalities) in DNA repair genes. The data showed that treatment with olaparib was associated with a reduction in pain and...
Read MoreEvaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.
In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA was effective with manageable side effects for these patients. Some background Prostate cancer (PC) often grows in...
Read MoreEvaluating the effectiveness and safety of 225Ac-PSMA-617 after treatment with androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer.
In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) after treatment with androgen deprivation therapy (ADT) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA treatment showed a higher response with manageable effects in these patients. Some...
Read MoreComparing the effectiveness and safety of apalutamide with darolutamide for non-metastatic castration-resistant prostate cancer.
In a nutshell The study compared the effectiveness and safety outcomes of androgen-deprivation therapy (ADT) with either apalutamide (Erleada) or darolutamide (Nubeqa) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC). The data showed that apalutamide plus ADT was safe and more effective in improving...
Read MoreComparing outcomes after robot‑assisted and laparoscopic prostate surgery for patients with localized prostate cancer with a large prostate volume.
In a nutshell This study compared the surgical, functional, and oncological outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer (PCa) with a large prostate volume. The study found that RARP was associated with better surgical,...
Read MoreEvaluating the long-term functional and oncological outcomes after open versus robot-assisted prostate surgery for localized prostate cancer.
In a nutshell This study evaluated the long-term functional and oncological outcomes of robotic-assisted laparoscopic radical prostatectomy (RALP) and open retropubic radical prostatectomy (RRP) for the treatment of patients with localized prostate cancer (PCa). This study found that RALP was associated with better oncological outcomes compared to...
Read MoreComparing the outcomes between prostate surgery and different types of radiotherapy in older patients with prostate cancer.
In a nutshell This study compared the outcomes between radical prostatectomy (RP; prostate-removal surgery) and different types of radiotherapy (RT) in older patients with localized prostate cancer (PCa). The study found that RT offers similar cancer-specific outcomes to RP for low- to intermediate-risk patients. Some background...
Read MoreComparing outcomes for prostate surgery versus radiation therapy for localized prostate cancer
In a nutshell The study aimed to compare the effectiveness of surgery versus radiation therapy for patients with high-grade localized prostate cancer (PCa). The study concluded that surgery was associated with improved survival compared to radiation therapy in these patients. Some background Prostate cancer (PCa) is the second most common...
Read MoreEvaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.
In a nutshell This study evaluated the effectiveness of salvage radiotherapy (RT) in patients with recurrence of prostate cancer (PCa) after prostate surgery. The study found that salvage RT was effective in the management of PCa recurrence with manageable side effects. Some background Localized prostate cancer (PCa) is a form of cancer that...
Read More